About half of patients receiving the procedure did not need medication to control their blood pressure after 5 years.
Bariatric surgery may be a viable option for long-term hypertension remission in patients with obesity-related high blood pressure, according to a new report.
A study published today in Journal of the American College of Cardiology1 shows patients with obesity and hypertension who underwent bariatric surgery achieved long-term reductions in blood pressure while taking fewer medications compared with a cohort of patients who received blood pressure medication alone.
The study authors wrote that the study shows the importance of treating obesity, a medical condition they said is often overlooked.
“As a consequence, there is a frequent failure in approaching obesity as a crucial step for mitigating the risk of important cardiovascular risk factors including hypertension, they said.
To gauge the long-term impact of bariatric surgery on hypertension, they recruited 100 people with grade 1 or 2 obesity who also had diagnosed hypertension. People with previous cardiovascular events or poorly controlled type 2 diabetes were excluded from the trial, which was named the GATEWAY (GAstric Bypass to Treat obEse Patients With steAdy hYpertension) trial.
Seventy-six percent of the participants were female. The group had a mean age of 43.8 years and a mean body mass index (BMI) or 36.9 kg/m2. All the patients were taking at least 2 medications. The participants were randomly assigned to receive Roux-en-Y gastric bypass (RYGB) procedures combined with medical therapy or medical therapy alone. The recruitment and follow-up period lasted from 2013 to January 2022. Follow-up took place after 5 years.
Sixty-nine patients were included in the final analysis (37 from the RYGB group and 32 from the medical therapy group). Most of the rest of the participants were lost to follow-up, although 4 patients in the RYGB group did not undergo the procedure and 1 patient in the medication-only group withdrew consent after being randomized to that group.
After 5 years, the patients in the RYGB group had a mean BMI of 28.01 kg/m2 compared with 36.40 kg/m2 for the medication-only group. Those who received the surgery had an 80.7% reduction in the number of medications they were taking, and 46.9% of those participants achieved hypertension remission, meaning they were able to control their blood pressure without needing medication. By comparison, the medication-only group had a modest reduction of 13.7% in the number of medications used, and only 2.4% of participants in that group achieved hypertension remission.
“In our study, we demonstrated that bariatric surgery promotes favorable and sustainable effects in several related [hypertension] parameters in subjects with obesity grades 1 and 2,” the study investigators wrote.
The authors acknowledged that much of the momentum around obesity treatment has been focused on new medications, such as semaglutide (Wegovy; Novo Nordisk), that have led to dramatic weight loss in many patients without the need for surgery. However, they said there has not yet been a randomized controlled trial looking specifically at how the newer therapies affect blood pressure over a long time horizon, and they also noted that such drugs require long-term use and come with a high cost.
They noted several limitations to their study. It was a single-center study with a relatively small sample size, and it was not powered to evaluate hard outcomes like mortality and major cardiac events.
An accompanying editorial2 said the trial provides important long-term data showing the benefits for RYGB on weight loss and blood pressure.
“Further studies assessing the threshold mean body mass index vs other measures of adiposity) for bariatric surgery in people with obesity, optimal timing of bariatric surgery in obese people with cardiometabolic diseases (eg, after certain duration of obesity), type of bariatric surgery (RYGB vs sleeve gastrectomy), and comparative studies of obesity pharmacotherapies and bariatric surgery are needed to clarify the optimal treatment pathways for this common and growing disease,” they concluded.
References
AA Unlikely to Cause Anxiety, Depression but May Be Affected by Mental Illness
May 7th 2024A Mendelian randomization study using genetic analysis found that alopecia areata (AA) increases the risk of anxiety and depression, but not the other way around, providing unique evidence for a causal link while adding to existing evidence.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Access Denied: CMS’ Action Hurts Patients With Cancer in Rural America
May 6th 2024CMS rules hindered the access of rural patients with cancer to medically integrated pharmacies in 2023. The authors discuss the impact on equity in health care, emphasizing the need for regulatory change.
Read More
What Mass General Brigham Is Doing to Combat Prostate Cancer Disparities Among Men of Color
May 5th 2024Quoc-Dien Trinh, MD, MBA, chief of urology at Brigham & Women's Faulkner Hospital, highlighted successful efforts to improve prostate cancer care access for underserved communities in Massachusetts.
Read More